In RCC cells the Bcl-2 inhibition combined with cisplatin exerts the therapeutic effects of cisplatin providing an attractive therapeutic strategy in Bcl-2 overexpressing RCCs. This evidence concerns the gene BCL2 and renal cell adenocarcinoma.